AHIMA launch new EU collaboration in AI and Telehealth.

The American Health Information Management Association (AHIMA) and Frontiers Health, along with  the Healthware Group, recently agreed to a content collaboration that will serve health care professionals in both Europe and the United States.

It comes just prior to the launch of the annual AHIMA Conference, this time Virtual, in just 10 days time. (We will be talking with Michael Bittner, AHIMA Media Director, early next week, on  the key notes to be covered)  In meantime – What they say is this:

“Frontiers Health is recognized across Europe as a transformative organization with a long history of promoting innovation in health care,” said AHIMA CEO Wylecia Wiggs Harris, PhD, CAE. “Like AHIMA, they see the human behind health information and health policy, making our collaboration a natural fit.”

Frontiers Health, in cooperation with Healthware Group, is hosting two education sessions, focusing on telehealth and artificial intelligence in health care, at the AHIMA20 Virtual Conference taking place October 14-17. The sessions will feature speakers from companies like CarePredict, Intouch Group, Kaia Health, Vitality, and Wysa, as well as other global players from the digital health space.

In addition, both organizations will collaborate on sessions at the Frontiers Health Hybrid Conference this November. AHIMA’s international team will host several sessions within an overarching theme of “Data Driving the Future of Health.” AHIMA experts will discuss data consent, privacy, interoperability, patient access to their health information, and more.

“This collaboration serves AHIMA members and health care professionals in Europe, as both groups will have access to new content and resources with a global perspective,” Harris said. “It will also help AHIMA increase its international footprint and reach health care audiences around the world.”

“I am pleased to expand our collaboration with AHIMA and look forward to hosting two dedicated Frontiers Health sessions at the AHIMA20 Virtual Conference,” said Roberto Ascione, conference chairman of Frontiers Health and CEO & founder at Healthware Group. “Frontiers Health will share its extensive knowledge and first-hand experience in strategic spaces like telehealth and artificial intelligence. Through its cooperation with AHIMA, Frontiers Health will promote and contribute to the pivotal role of digital health innovation in the new normal.”

Welcome to our Annual Himss Orlando 2020 Survey

The cancellation of this year’s HIMSS 2020 – has left a hole for many vendors, as to how to reach out to their necessary market, and the reverse, how can hospitals and clinicians follow what is going on?

Every year we receive about one hundred or so requests for interviews and editorials, from PR companies and their healthcare clients. We take here what we feel are the most interesting of these and most relevant, and simply tell it like it is. We publish what they themselves have to say. And we invite you to make direct contact with the vendors concerned. Access to our report will cost you around $2.00, which goes towards our costs of putting the data together for you. And you can use our search bar on our site, to find any topic that might not be immediately visible that we might have spoken about here or earlier.

So.. here we go!

Is AI finally getting traction in Healthcare?

Ahead of Rare Disease Day (Feb 29), Ashley Yum has written to us,  to offer us the opportunity to speak with Steve Costalas, CEO, HVH Precision Analytics, about how AI and machine learning are being used to help diagnose rare diseases faster and more accurately.

HVH Precision Analytics is a joint venture between the world’s largest health and wellness network Havas Health & You , and Vencore,  and specializes in AI and machine learning data analytics.

At a time when take up of AI in healthcare is surprisingly low, this collaboration is looking at  how AI/big data can identify symptoms of disease 3-5 years before diagnosis, – and using RWD and RWE to find undiagnosed patients in healthcare databases – and finally, – · leveraging data to support the rare disease community beyond diagnosis.

And they have some interesting side announcements, if you will…

95% of rare diseases do not have an FDA-approved treatment, significantly limiting treatment options for the 400 million people living with a rare disease.

7,000 rare diseases have been identified, but only 5% have FDA-approved treatments.

The total number of Americans living with a rare disease is estimated at between 25-30 million.

The average time it takes for rare disease patients to receive an accurate diagnosis is 4.8 years.

However, they are  excited about the progress that’s been made in recent years thanks to AI, and  they would love to share  what they  think is in store for the future.

Ashley can be contacted at; ashley.yum@HVHprecision.com